Momenta Pharmaceuticals (MNTA) PT Lifted to $24 at Leerink Partners on Generic Copaxone Approval
Tweet Send to a Friend
Leerink Partners analyst Jason Gerberry reiterated an Outperform rating and raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE